Our Company

Our Company

Corporate Responsibility

Leadership

Corporate Responsibility

Disclosures

Derived from the expression 'securing health for all of us', CSL Seqirus has public health protection at its core.
Learn more

At CSL Seqirus, Corporate Responsibility is about conducting our business ethically and contributing to the economic, social and environmental well-being of our communities.
Learn more
Expertise

Expertise

Influenza

Influenza

Pandemic Response Solutions

CSL Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the U.S., U.K. and Australia.
Learn more

CSL Seqirus is on the front line of battling influenza, working hard to suppress costly and life-threatening epidemics and pandemics. Vaccination is the most effective way to prevent influenza .
Learn more
Products
Careers

Careers

See Yourself at CSL Seqirus

Discover Our People

Diversity and Inclusion

How we care for you at CSL Seqirus

When you join CSL Seqirus, you join a team dedicated to protecting people and communities from influenza. It's a feeling of purpose and possibility that inspires us every day.
Learn more

It doesn't matter whether you are a scientist or an administrator, a marketer or an operator - as long as you are inspired by the chance to create something that will help others, you can find your role at CSL Seqirus.
Learn more

Popular search terms:

Search Results

13 results found

US Media Release Template Q3 2013

About Seqirus Seqirus is the new global company created in July 2015 from the combined strength and expertise of bioCSL Inc. and the influenza vaccines business formerly owned by Novartis AG.

https://www.cslseqirus.us/-/media/seqirus-us/news/franchise-shipment-press-release--71116final-530-pm.pdf
Seqirus announces next major advancement in cell-based influenza vaccine technology

In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.

https://www.cslseqirus.us/news/seqirus-announces-next-major-advancement-in-cell-based-influenza-vaccine-technology
Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors

Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older

https://www.cslseqirus.us/news/be-fluent-partnership-shines-spotlight-on-importance-of-flu-prevention-in-seniors